Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 3
2010 2
2014 2
2015 3
2016 3
2017 2
2018 3
2020 1
2021 1
2022 2
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 3 Nausea, CTCAE"
Page 1
Age as a potential predictor of acute side effects during chemoradiotherapy in primary cervical cancer patients.
Holmqvist A, Lindahl G, Mikivier R, Uppungunduri S. Holmqvist A, et al. BMC Cancer. 2022 Apr 7;22(1):371. doi: 10.1186/s12885-022-09480-w. BMC Cancer. 2022. PMID: 35392858 Free PMC article.

RESULTS: Patients 52 years had a significantly higher frequency of nausea/vomiting and increased grade 3 toxicity during CRT compared to younger patients (p < 0.001, p = 0.001). Toxicity grade 3 of nausea/vomiting was associated with i

…
RESULTS: Patients 52 years had a significantly higher frequency of nausea/vomiting and increased grade 3 toxicity durin …
Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Holyoake DLP, Warren DR, Hurt C, Aznar M, Partridge M, Mukherjee S, Hawkins MA. Holyoake DLP, et al. Clin Oncol (R Coll Radiol). 2018 Jul;30(7):418-426. doi: 10.1016/j.clon.2018.02.067. Epub 2018 Mar 28. Clin Oncol (R Coll Radiol). 2018. PMID: 29602584 Clinical Trial.
The outcome measures used were Common Terminology Criteria of Adverse Events (CTCAE) grade and risk of CTCAE grade 2 acute upper gastrointestinal toxicity (anorexia, pain, nausea and/or vomiting). The risk of CTCAE grade 2 events w …
The outcome measures used were Common Terminology Criteria of Adverse Events (CTCAE) grade and risk of CTCAE grade …
Phase II Trial of Flaxseed to Prevent Acute Complications After Chemoradiation for Lung Cancer.
Lim TL, Pietrofesa RA, Arguiri E, Koumenis C, Feigenberg S, Simone CB 2nd, Rengan R, Cengel K, Levin WP, Christofidou-Solomidou M, Berman AT. Lim TL, et al. J Altern Complement Med. 2021 Oct;27(10):824-831. doi: 10.1089/acm.2020.0542. Epub 2021 Jun 23. J Altern Complement Med. 2021. PMID: 34161146 Clinical Trial.
The primary outcomes were overall adverse events, with particular focus on Grade 3 RP, and flaxseed tolerability. Adverse events were graded according to CTCAE v4.0. ...There were no cases of Grade 2 RP. Six patients (32%) developed Grade …
The primary outcomes were overall adverse events, with particular focus on Grade 3 RP, and flaxseed tolerability. Adverse even …
Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials.
Freyer DR, Lin L, Mack JW, Maurer SH, McFatrich M, Baker JN, Jacobs SS, Lucas N, Withycombe JS, Tomlinson D, Villabroza KR, Waldron MK, Hinds PS, Reeve BB. Freyer DR, et al. J Clin Oncol. 2022 May 20;40(15):1623-1634. doi: 10.1200/JCO.21.02669. Epub 2022 Mar 16. J Clin Oncol. 2022. PMID: 35294262 Free PMC article.
PURPOSE: To examine concordance in symptomatic adverse event (AE) grading using the Common Terminology Criteria for Adverse Events (CTCAE 4.0) for clinicians and its patient-reported outcome (PRO) versions for children (Ped-PRO-CTCAE) and caregivers (Ped-PRO- …
PURPOSE: To examine concordance in symptomatic adverse event (AE) grading using the Common Terminology Criteria for Adverse Events ( …
Liver injury with COVID-19 based on gastrointestinal symptoms and pneumonia severity.
Kaneko S, Kurosaki M, Nagata K, Taki R, Ueda K, Hanada S, Takayama K, Suzaki S, Harada N, Sugiyama T, Nagasawa M, Izumi N. Kaneko S, et al. PLoS One. 2020 Nov 4;15(11):e0241663. doi: 10.1371/journal.pone.0241663. eCollection 2020. PLoS One. 2020. PMID: 33147270 Free PMC article.
The factors of liver injury especially on the elevation of liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) were analyzed. Grading was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. .. …
The factors of liver injury especially on the elevation of liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT …
Adverse drug events and contributing factors among pediatric cancer patients at Jimma University medical center, Southwest Ethiopia.
Tola WO, Melaku T, Fufa D, Sheleme T. Tola WO, et al. BMC Pediatr. 2023 Feb 13;23(1):77. doi: 10.1186/s12887-023-03891-9. BMC Pediatr. 2023. PMID: 36782170 Free PMC article.
The most common ADEs were hematologic toxicities (anemia 55(11.8%), neutropenia 52(11.16%) & thrombocytopenia 31(6.65%)), and gastrointestinal effects (nausea 46(9.87%), vomiting 46(9.87%), anorexia 41(8.8%). Out of 466 ADEs, 150 (32.19%) were classified as common term …
The most common ADEs were hematologic toxicities (anemia 55(11.8%), neutropenia 52(11.16%) & thrombocytopenia 31(6.65%)), and gastrointe …
Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study.
Visacri MB, Pincinato EC, Ferrari GB, Quintanilha JCF, Mazzola PG, Lima CSP, Moriel P. Visacri MB, et al. Daru. 2017 Apr 24;25(1):12. doi: 10.1186/s40199-017-0178-9. Daru. 2017. PMID: 28438219 Free PMC article.
The most frequently observed ADRs were anaemia (81.4%), lymphopenia (78%), and nausea (64.4%); mostly grades 1 and 2 of toxicity. The mean cisplatin excretion was 70.3 64.4, 7.3 6.3, and 5 4 mug/mg creatinine at 0-12, 12-24, and 24-48 h, respect …
The most frequently observed ADRs were anaemia (81.4%), lymphopenia (78%), and nausea (64.4%); mostly grades 1 and 2 of toxici …
A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P. Ferrarotto R, et al. Ann Oncol. 2018 Jul 1;29(7):1561-1568. doi: 10.1093/annonc/mdy171. Ann Oncol. 2018. PMID: 29726923 Free article. Clinical Trial.
Adverse events were graded according to the NCI-CTCAE v 4.03. Efficacy was assessed by RECIST 1.1. RESULTS: Forty-eight subjects enrolled (33 in dose escalation and 15 in the expansion phase). The MTD was 1.5 mg/kg Q3W. Dose-limiting toxicities were grade …
Adverse events were graded according to the NCI-CTCAE v 4.03. Efficacy was assessed by RECIST 1.1. RESULTS: Forty-eight subjec …
A Phase 0/I Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas.
Desai PB, Karve AS, Zawit M, Arora P, Dave N, Awosika J, Li N, Fuhrman B, Medvedovic M, Sallans L, Kendler A, DasGupta B, Plas D, Curry R, Zuccarello M, Chaudhary R, Sengupta S, Wise-Draper TM. Desai PB, et al. Clin Cancer Res. 2024 May 15;30(10):2068-2077. doi: 10.1158/1078-0432.CCR-23-3341. Clin Cancer Res. 2024. PMID: 38530160 Clinical Trial.
PURPOSE: High-grade gliomas (HGG) carry a poor prognosis, with glioblastoma accounting for almost 50% of primary brain malignancies in the elderly. ...The recommended phase 2 dose (R2PD) was determined as the dose that resulted in predicted steady-state tumor …
PURPOSE: High-grade gliomas (HGG) carry a poor prognosis, with glioblastoma accounting for almost 50% of primary brain maligna …
Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.
Rochet N, Lindel K, Katayama S, Schubert K, Herfarth K, Schneeweiss A, Sohn C, Harms W, Debus J. Rochet N, et al. Strahlenther Onkol. 2015 Jul;191(7):582-9. doi: 10.1007/s00066-015-0830-6. Epub 2015 Mar 19. Strahlenther Onkol. 2015. PMID: 25786589 Clinical Trial.
RESULTS: Median follow-up was 44 months (range 19.2-67.2 months). No grade 4 toxicities occurred during IM-WAI. Common Toxicity Criteria for Adverse Events (CTCAE) grade 3 toxicities were: diarrhea (25 %), leucopenia (19 %), nausea/vomiting (6 % …
RESULTS: Median follow-up was 44 months (range 19.2-67.2 months). No grade 4 toxicities occurred during IM-WAI. Common Toxicity Crite …
25 results